Recombinant Activated Factor VII (rFVIIa): Characterization, Manufacturing, and Clinical Development

Birgit Jurlander; Lars Thim; Niels K. Klausen; Egon Persson; Marianne Kjalke; Per Rexen; Tom B. Jørgensen; Per B. Østergaard; Elisabeth Erhardtsen; Søren E. Bjørn

doi:10.1055/s-2001-16890

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2001; 27(4): 373-384
DOI: 10.1055/s-2001-16890

Recombinant Activated Factor VII (rFVIIa): Characterization, Manufacturing, and Clinical Development

Birgit Jurlander¹ , Lars Thim² , Niels K. Klausen³ , Egon Persson⁴ , Marianne Kjalke⁴ , Per Rexen⁵ , Tom B. Jørgensen⁵ , Per B. Østergaard⁶ , Elisabeth Erhardtsen⁷ , Søren E. Bjørn²

¹IO Biopharm, Novo Nordisk A/S, Lyngby, Denmark
²Protein Chemistry, Novo Nordisk A/S, Lyngby, Denmark
³Protein Drug Delivery, Novo Nordisk A/S, Lyngby, Denmark
⁴Vascular Biochemistry, Novo Nordisk A/S, Lyngby, Denmark
⁵Factor VIIa Bulk Production, Novo Nordisk A/S, Lyngby, Denmark
⁶Regulatory Affairs, Novo Nordisk A/S, Lyngby, Denmark
⁷Clinical Development, Novo Nordisk A/S, Lyngby, Denmark

Abstract

ABSTRACT

Recombinant activated coagulation factor VII (rFVIIa) (NovoSeven®) was developed for treatment of bleeding in hemophilia patients with inhibitors (antibodies) against factors VIII or IX. rFVIIa initiates the coagulation cascade by binding to tissue factor at the site of injury and causes the formation of sufficient amounts of thrombin to trigger coagulation. Patients with a variety of other coagulation deficiencies than hemophilia characterized by an impaired thrombin generation and life-threatening bleeding have been reported as successfully treated with rFVIIa. Data are now entered into clinical registries established to further monitor this experimental treatment with NovoSeven®. rFVIIa is produced free of any added human protein. The amino acid sequence of rFVIIa is identical to plasma-derived FVIIa (pdFVIIa). Posttranslational modifications (i.e., γ-carboxylations, N- and O-glycosylations) are qualitatively identical in pdFVIIa and rFVIIa although some quantitative differences exist. The activities of rFVIIa and pdFVIIa are indistinguishable. Manufacturing of rFVIIa involves expression in baby hamster kidney (BHK) cells followed by purification, including three ion-exchange and one immunoaffinity chromatography steps. The last anion-exchange chromatography step ensures completion of the autoactivation of recombinant factor VII (rFVII) to rFVIIa. This review describes the mechanism of action, characterization, manufacturing, and preclinical and current clinical evidence for the efficacy and safety of rFVIIa.

KEYWORD

Factor VIIa - rFVIIa - recombinant expression - in vitro activation - biological activity

Full Text

References

REFERENCES

1 Key N S, Aledort L M, Beardsley D. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost . 1998; 80 912-918
2 Shapiro A D, Gilchrist G S, Hoots W K, Cooper H A, Gastineau D A. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost . 1998; 80 773-778
3 Lusher J M, Roberts H R, Davignon G. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia . 1998; 4 790-798
4 Ingerslev J, Freidman D, Gastineau D. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis . 1996; 26(Suppl 1) 118-123
5 Hay C R, Negrier C, Ludlam C A. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost . 1997; 78 1463-1467
6 Liebman H A, Chediak J, Fink K I. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol . 2000; 63 109-113
7 Arkin S, Cooper H A, Hutter J J. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the NovoSeven emergency-use program. Haemostasis . 1998; 28 93-98
8 Green D, Lechner K A. A survey of 215 non-haemophiliac patients with inhibitors to factor VIII. Thromb Haemost . 1981; 45 200-203
9 Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia . 1999; 5(Suppl 3) 11-17
10 Conlan M G, Hoots W K. Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery. Am J Hematol . 1990; 35 203-207
11 Lusher J M. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol . 1998; 61(Suppl) 7-10
12 Mariani G, Testa M G, Di Paolantonio T, Molskov B R, Hedner U. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang . 1999; 77 131-136
13 Ingerslev J, Knudsen L, Hvid I. Use of recombinant factor VIIa in surgery in factor VII deficient patients. Haemophilia . 1997; 3 215-218
14 Hunault M, Bauer K A. Recombinant factor VIIa for the treatment of congenital factor VII deficiency. Semin Thromb Hemost . 2000; 26 401-405
15 Ingerslev J, Sneppen O, Hvid I. Treatment of acute bleeding episodes with rFVIIa. Vox Sang . 1999; 77(Suppl 1) 42-46
16 Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost . 2000; 26 425-432
17 Monroe D M, Hoffman M, Allen G, Roberts H. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost . 2000; 26 373-377
18 Roberts H, Monroe D M, Hoffman M. Molecular biology and biochemistry of the coagulation factors and pathways of haemostasis. In: Beutler E, Lichtman MA, Coller BS, Kipps, TJ, Seligsohn U, eds. Williams' Hematology New York: McGraw-Hill; 2001: 1409-1434
19 Morrissey J H, Macik B G, Neuenschwander P F, Comp P C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood . 1993; 81 734-744
20 Wildgoose P, Nemerson Y, Hansen L L. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood . 1992; 80 25-28
21 van't Veer C, Golden N J, Mann K G. Inhibition of thrombin generation by the zymogen factor VII: Implications for the treatment of hemophilia A by factor VIIa. Blood . 2000; 95 1330-1335
22 Monroe D M, Hoffman M, Oliver J A, Roberts H R. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol . 1997; 99 542-547
23 Hagen F, Gray L, O'Hara P. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA . 1986; 83 2412-2416
24 Banner D, D'Arcy A, Chene C. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature . 1996; 380 41-46
25 Persson E, Petersen L C. Structurally and functionally distinct Ca²⁺ binding sites in the gamma-carboxyglutamic acid-containing domain of factor VIIa. Eur J Biochem . 1995; 234 293-300
26 Persson E, Olsen O H, Østergaard A, Nielsen L S. Ca²⁺ binding to the first epidermal growth factor-like domain of factor VIIa increases amidolytic activity and tissue factor affinity. J Biol Chem . 1997; 272 19919-19924
27 Wildgoose P, Foster D, Schiødt J. Identification of a calcium site in the protease domain of human blood coagulation factor VII: evidence for its role in factor VIIa-tissue factor interaction. Biochemistry . 1993; 32 114-119
28 Bom V JJ, Bertina R M. The contributions of Ca²⁺, phospholipids and tissue factor apoprotein to activation of human blood coagulation factor X by activated factor VII. Biochem J . 1990; 265 327-336
29 Freskgard P O, Olsen O H, Persson E. Structural changes in factor VIIa induced by Ca²⁺ and tissue factor studied using circular dichroism spectroscopy. Protein Sci . 1996; 5 1531-1540
30 Pike A CW, Brzozowski A M, Roberts S M, Olsen O H, Persson E. Structure of human factor VIIa and its implications for the triggering of blood coagulation. Proc Natl Acad Sci USA . 1999; 96 8925-8930
31 Ruf W, Dickinson C D. Allosteric regulation of the cofactor-dependent serine protease coagulation factor VIIa. Trends Cardiovasc Med . 1998; 8 350-356
32 Thim L, Bjoern S, Christensen M. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry . 1988; 27 7785-7793
33 Lund-Hansen T, Petersen L C. Comparison of enzymatic properties of human plasma FVIIa and human recombinant FVIIa. Thromb Haemost . 1987; 58 270 Abstract
34 Persson E, Nielsen L S. Site-directed mutagenesis but not gamma-carboxylation of Glu-35 in factor VIIa affects the association with tissue factor. FEBS Lett . 1996; 385 241-243
35 Drakenberg T, Fernlund P, Roepstorff P, Stenflo J. Beta-hydroxyarspartic acid in vitamin K-dependent protein C. Proc Natl Acad Sci USA . 1983; 80 1802-1806
36 McMullen B A, Fujikawa K, Kisiel W. The occurrence of beta-hydroxyaspartic acid in the vitamin K-dependent blood coagulation zymogens. Biochem Biophys Res Commun . 1983; 115 8-14
37 Bjoern S, Foster D, Thim L. Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine. J Biol Chem . 1991; 266 11051-11057
38 Kentzer E J, Buko A, Meno G, Sarin V K. Carbohydrate composition and presence of a fucose-protein linkage in recombinant human pro-urokinase. Biochem Biophys Res Commun . 1990; 171 401-406
39 Nishimura H, Kawabata S, Kisiel W. Identification of a disaccharide (Xyl-Glc) and trisaccharide (Xyl2-Glc) O-glycosidically linked to a serine residue in the first epidermal growth factor-like domain of human factors VII and IX and protein Z and bovine protein Z. J Biol Chem . 1989; 264 20320-20325
40 Lino M, Foster D C, Kisiel W. Functional consequences of mutations in Ser-52 and Ser-60 in human blood coagulation factor VII. Arch Biochem Biophys . 1998; 352 182-192
41 Klausen N K, Kornfelt T. Analysis of the glycoforms of human recombinant factor VIIa by capillary electrophoresis and high-performance liquid chromatography. J Chromatogr A . 1995; 718 195-202
42 Klausen N K, Bayne S, Palm L. Analysis of site-specific asparagine-linked glycosylation of recombinant human coagulation factor VIIa by glycosidase digestions, liquid chromatography, and mass spectrometry. Mol Biotechnol . 1996; 9 195-204
43 Palm L, Roepstorff P, Klausen N K. Elucidation of N-linked carbohydrate structures in recombinant human factor VII (rFVIIa) by combination of MALDI-MS and glycosidase digestions. XVIII International Carbohydrate Symposium, July 1996, Milano, Italy 1996
44 Weber P L, Kornfelt T, Klausen N K, Lunte S M. Characterization of glycopeptides from recombinant coagulation factor VIIa by high-performance liquid chromatography and capillary zone electrophoresis using ultraviolet and pulsed electrochemical detection. Anal Biochem . 1995; 225 135-142
45 Berkner K, Busby S, Davie E. Isolation and expression of cDNAs encoding for human factor VII. Cold Spring Harb Symp Quant Biol . 1986; 51 531-541
46 Butenas S, Mann K G. Kinetics of human factor VII activation. Biochemistry . 1996; 35 1904-1910
47 Bjoern S, Thim L. Activation of coagulation factor VII to VIIa. Res Discl . 1986; 269 564-565
48 Wildgoose P, Berkner K, Kisiel W. Synthesis, purification, and characterization of an Arg152Glu site-directed mutant of recombinant human blood clotting factor VII. Biochemistry . 1990; 29 3413-3420
49 Brinkhous K M, Hedner U, Garris J B, Diness V, Read M S. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci USA . 1989; 86 1382-1386
50 Diness V, Lund-Hansen T, Hedner U. Effect of recombinant human FVIIA on warfarin-induced bleeding in rats. Thromb Res . 1990; 59 921-929
51 Diness V, Bregengaard C, Erhardtsen E, Hedner U. Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thromb Res . 1992; 67 233-241
52 Erhardtsen E, Nony P, Dechavanne M. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0 Blood Coagul Fibrinolysis . 1998; 9 741-748
53 Lindley C M, Sawyer W T, Macik B G. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther . 1994; 55 638-648
54 Hedner U, Kristensen H, Berntorp E. Pharmacokinetics of rFVIIa in children. Haemophilia . 1998; 4 355 (Abst)
55 Girard P, Nony P, Erhardtsen E. Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. Thromb Haemost . 1998; 80 109-113
56 Erhardtsen E. Pharmacokinetics of recombinant activated factor VII. Semin Thromb Hemost . 2000; 26 385-391
57 Johannessen M, Andreasen R B, Nordfang O. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven. Blood Coagul Fibrinolysis . 2000; 11 239-242
58 Brackmann H H, Effenberger W, Hess L, Schwaab R, Oldenburg J. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?. Eur J Haematol . 1998; 61(Suppl 63) 18-23
59 Kobelt R. A Swiss treatment concept for the use of rFVIIa in the context of immune tolerance therapy. In: Scharrer I, von Depka Prondzinski M, eds. Recombinant Factor VIIa Current and Future Indications. Frankfurt/Main, Germany: Weller Verlag; 2000: 50-57
60 Manno S C. Treatment options for bleeding episodes in patients undergoing immune tolerance therapy. Haemophilia . 1999; 5(Suppl 3) 33-41
61 Bernstein D E, Jeffers L, Erhardtsen E. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology . 1997; 113 1930-1937
62 Holm M, Andreasen R, Ingerslev J. Management of bleeding using recombinant factor VIIa in patients suffering from bleeding tendency due to a lupus anticoagulant-hypoprothrombinemia syndrome. Thromb Haemost . 1999; 82 1776-1778
63 Muleo G, Santoro R, Iannaccaro P G. Small doses of recombinant factor VIIa in acquired deficiencies of vitamin K dependent factors. Blood Coagul Fibrinolysis . 1999; 10 521-522
64 Kristensen J, Killander A, Hippe E. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis . 1996; 26(Suppl 1) 159-164
65 Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost . 1998; 80 352 Lett
66 Poon M C, Demers C, Jobin F, Wu J W. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood . 1999; 94 3951-3953
67 Meijer K, Sieders E, Slooff M JH, de Wolf T M J, van der Meer J. Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII. Thromb Haemost . 1998; 80 204-205
68 Martinowitz U, Kenet G, Onaca M D. New treatment of uncontrolled hemorage in trauma/surgical patients: induction of local hypercoagulation. American Association for the Surgery of Trauma 60th Annual Meeting, San Antonio, Texas, Session IX, 2000; Abst 48
69 Vlot A J, Ton E, Mackaay A JC, Kramer M HH, Gaillard C J M A. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am J Med . 2000; 108 421-422
70 Liem A S E K, Biesma D W, Ernst S P G M, Schepens M A M A. Recombinant activated factor VII for false aneurisms in patiens with normal haemostatic mechanisms. Thromb Haemost . 1999; 82 150-151
71 Moisescu E, Ardelean I, Simion I, Muresen A, Ciupan R. Recombinant factor VIIa treatment of bleeding associated with acute renal failure. Blood Coagul Fibrinolysis . 2000; 11 575-577
72 Revesz T, Arets B, Bierings M, van den Bos C, Duval E. Recombinant factor VIIa in severe uremic bleeding. Thromb Haemost . 1998; 80 353 Lett
73 Rice K M, Savidge G F. NovoSeven (recombinant factor VIIa) in centeral nervous system bleeds. Haemostasis . 1996; 26(Suppl 1) 131-134